Geode Capital Management’s Petros Pharmaceuticals PTPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,327
| Closed | -$7.47K | – | 4506 |
|
|
2025
Q1 | $7.47K | Buy |
4,327
+2,880
| +199% | +$14.7K | ﹤0.01% | 4445 |
|
|
2024
Q4 | $14.3K | Sell |
1,447
-54
| -4% | -$441 | ﹤0.01% | 4413 |
|
|
2024
Q3 | $13.4K | Buy |
1,501
+286
| +24% | +$2.68K | ﹤0.01% | 4442 |
|
|
2024
Q2 | $13.9K | Buy |
1,215
+795
| +189% | +$12.8K | ﹤0.01% | 4511 |
|
|
2024
Q1 | $15.5K | Hold |
420
| – | – | ﹤0.01% | 4511 |
|
|
2023
Q4 | $14.9K | Hold |
420
| – | – | ﹤0.01% | 4554 |
|
|
2023
Q3 | $17.4K | Buy |
+420
| New | +$28.8K | ﹤0.01% | 4648 |
|
|
2022
Q4 | – | Sell |
-307
| Closed | -$39K | – | 4924 |
|
|
2022
Q3 | $39K | Buy |
307
+6
| +2% | +$1.09K | ﹤0.01% | 4813 |
|
|
2022
Q2 | $61K | Buy |
301
+21
| +8% | +$5.26K | ﹤0.01% | 4731 |
|
|
2022
Q1 | $109K | Buy |
280
+45
| +19% | +$19K | ﹤0.01% | 4630 |
|
|
2021
Q4 | $195K | Buy |
235
+140
| +147% | +$82K | ﹤0.01% | 4485 |
|
|
2021
Q3 | $47K | Hold |
95
| – | – | ﹤0.01% | 4792 |
|
|
2021
Q2 | $74K | Buy |
95
+38
| +67% | +$30.4K | ﹤0.01% | 4610 |
|
|
2021
Q1 | $52K | Buy |
+57
| New | +$53.7K | ﹤0.01% | 4397 |
|
Geode Capital Management's PTPI Position: Q2 2025 in Review
Geode Capital Management sold out of Petros Pharmaceuticals (PTPI) in Q2 2025, closing a stake of 4,327 shares — an estimated $7.47K sold.
Geode Capital Management first reported a position in PTPI in Q1 2021 and held it in 14 quarters. The position peaked at $195K in Q4 2021. 0 funds tracked by Wall St. Rank hold PTPI as of Q2 2025.
- Geode Capital Management reported no remaining Petros Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Geode Capital Management sold 4,327 Petros Pharmaceuticals shares in Q2 2025, an estimated $7.47K.
- Geode Capital Management first reported a position in Petros Pharmaceuticals in Q1 2021 and held it in 14 quarters.
- Geode Capital Management's Petros Pharmaceuticals position peaked at $195K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2025.
Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.